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ABSTRAK 
 
Sindrom ‘Fragile X’ lazimnya disebabkan oleh ketidakstabilan kembangan jujukan ulangan 
trinukleotid pada gen FMR-1. Warisannya adalah rantaian X diturunkan secara ‘reduce 
penetrance’ dan frekuensinya terus meningkat melalui beberapa generasi. Fenotip yang 
dimanifestasikan oleh sindrom ‘fragile X’ adalah tidak spesifik. Penganalisaan secara 
sitogenetik memerlukan pengalaman untuk mengenalpasti tapak rapuhan pada metafasis 
manakala analisis DNA seperti Pemblotan ‘Southern’ adalah sangat mahal apabila ia 
digunakan sebagai rujukan rutin saringan. Kajian ini bertujuan untuk memperkenalkan 
teknik berasaskan tindakbalas rantaian polimerase (‘Touch down PCR’) sebagai kaedah 
saringan sindrom ‘Fragile X’. Sejumlah enam kes telah dikajii. Antaranya, satu kes 
merupakan kes sindrom Fragile X (T1) yang telah dikenalpasti dengan kaedah sitogenetik 
konvensional, dua lagi merupakan ibu (T2) dan bapanya (T3). Dua kes yang lain (T4 dan 
T5) telah dipilih secara rawak daripada pesakit yang masing-masing menunjukkan ciri-ciri 
dismorfik dan kerencatan perkembangan. Satu kawalan normal (TC) juga dimasukkan. 
Analisis sitogenetik terhadap tapak rapuhan telah dijalankan. Dua sistem kultur digunakan, 
termasuk kultur ‘synchronized’ limfosit dan kultur kurangan folat-thimidin. Pencelupan 
metafasa dari kultur ‘fragile X’ dianalisis untuk kehadiran tapak rapuhan pada kromosom 
X. Kariotip daripada pencelupan saluran-G dibuat dengan alat penganalisa imejan untuk 
kesemua sampel yang dikaji bagi menyingkirkan kehadiran ketidaknormalan kromosom. 
DNA diekstrak daripada sampel-sampel ini dan digandakan dengan rantai polimerase 
‘Touch-Down’. Analisis sitogenetik menunjukkan satu tapak rapuhan sensitif-folat pada 
lelaki yang disyaki dan tapak rapuhan negatif pada lima sampel yang lain. Kariotip 
daripada pencelupan saluran-G menunjukkan tiada tambahan ketidaknormalan kromosom. 
Kesemua DNA yang diekstrak mengganda dengan baik. Lima daripada sampel kajian 
tapak rapuhan negatif menunjukkan kehadiran produk pada saluran yang dijangka iaitu 
522bp, yang menunjukkan tiada kembangan gen FRM-1. Namun, tiada produk PCR 
dikesan pada lelaki yang dijangkiti; keputusan ujian PCR menunjukkan beliau mungkin 
mengalami kembangan penuh gen FMR-1. Kajian kami menunjukkan bahawa ujian PCR 
adalah satu kaedah yang cepat dan  spesifik untuk menyaring alel normal dan mutasi 
penuh pada gen ‘Fragile X’. Kami mencadangkan ia digunakan sebagai kaedah pelengkap 
kepada analisis sitogenetik untuk mengesan gen FRAXA (Folate Sensitive Fragile Site at 
Xq28).  
 
Kata Kunci:  Gen FMR-1, Sindrom Fragile X, Polymerase chain reaction (PCR), Touch 
down PCR 
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ABSTRACT 
 
Fragile X syndrome is a result of  an unstable expansion of (CGG)n trinucleotide 
sequences in the FMR-1 (Fragile X Mental Retardation 1) gene site at Xq27. In a normal 
person, n ranges from 6 to 40 repeats with an average of 30 repeats, whereas in a 
mutated FMR1 gene the sequence is repeated several times over (stuttering gene). Full 
mutation occurs when n equals 200 repeats or more. Where n equals 50 to 200 repeats, it 
is a premutation. Fragile X occurs when the FMR-1 gene is unable to make normal 
amounts of usable Fragile X Mental Retardation Protein, or FMRP. The amount of FMRP 
in the body is one factor that determines the severity of the Fragile X syndrome. A person 
with nearly normal levels of FMRP usually has mild or no symptoms, while a person with 
very little or no normal FMRP has more severe symptoms. The mechanism for the role of 
the FMRP gene is still being researched upon. However, it has been observed that large 
numbers of repeats (more than 200) inactivates the gene through a process of methylation 
and when the gene is inactivated, the cell may make little or none of the needed FMRP. 
Inheritance is X-linked with reduced penetrance and the frequency of occurrence goes up 
through generations. The phenotypic manifestations of fragile-X syndrome vary and are 
largely dependent on the size of the mutation or premutation. The identification of the 
fragile site on G banded metaphases is a time consuming and delicate process requiring 
experience and skill, however, molecular diagnosis using DNA analysis and Southern 
blotting, even though expensive, is more specific in determining the presence or absence 
of the gene. This study was aimed to establish a rapid polymerase chain reaction (PCR) 
based - touch down PCR, as a screening method for fragile X syndrome. A total of six 
cases were analysed. Of these, one was a known case of Fragile X (T1) diagnosed by 
conventional cytogenetics, two were from the latter’s family members namely, his mother 
(T2) and father (T3), and the other two (T4 and T5) were randomly selected from patients 
presenting with dysmorphic features and delayed development respectively. One normal 
control (TC) was included. Cytogenetic analyses for detection of the fragile site was carried 
out in all cases. Two culture systems were used, namely the synchronised lymphocyte 
culture and the folate - thymidine deficient culture.  Stained metaphases from the fragile X 
cultures were screened for the presence of the fragile site on the X chromosome. G-
banded karyotyping was done using an image analyser to exclude presence of 
chromosomal abnormalities. DNA was extracted from these samples and amplified by 
touch-down PCR. Cytogenetic analysis revealed a folate-sensitive fragile site in the 
affected male, but none in the other five samples. G-banded karyotyping exhibited no 
additional chromosomal abnormalities. All extracted DNA samples were successfully 
amplified. Five of the samples showed presence of the product at the expected band at 
552bp, excluding the presence of an expansion of CGG segment of the FMR-1 gene. The 
absence of a band in an affected individual, suggested a fully mutated allele of FRAXA 
(Folate Sensitive Fragile Site at Xq28). We succeeded in establishing a slightly modified 
touch-down PCR analysis. Our study indicates that PCR testing offers a rapid and specific 
method for screening of normal allele and full mutation of the fragile X gene.  We suggest 
this technique to be applied as a complementary tool for cytogenetic analysis to detect the 
FRAXA gene.  
 
Key words:  FMR-1 gene, Fragile X syndrome, polymerase chain reaction (PCR), touch 
down PCR 
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INTRODUCTION 
 
Fragile X syndrome is caused by repetitive 
trinucleotide repeats (CGG)n, in the first 
exon of the fragile X mental retardation-1 
gene (FMR-1) of the X chromosome (Fu et 
al. 1991). When affected individuals have a 
large amplification, the DNA of the entire 5’ 
region of the gene becomes abnormally 
methylated. This is associated with methyl-
lation of an upstream gene promoter region 
(a CpG island) which results in transcript-
tional suppression of FMR-1, resulting in 
disease. Therefore, most affected males 
have no detectable FMR-1 mRNA, and it is 
believed to be the cause of the phenotype 
(Warren and Nelson 1994). At least three 
folate sensitive fragile sites, namely FRAX-
E, FRAXD, and FRAXF that map to distal 
Xq are involved, but only FRAXA is asso-
ciated with the fragile X syndrome (Parrish 
et al. 1994; Sheila et al. 2000). FRAXA is 
located on the chromosome X at position 
Xq27.3 (Jin and Warren 2000), near the 
end of the long arm. It is the most common 
cause of mental retardation. It is inherited 
as an X-linked dominant disorder with re-
duced penetrance with an incidence of 15-
20% of all X-linked mental retardation 
cases (Pergolizzi et al. 1992; Tarleton and 
Saul 1993; Warren and Nelson 1994). 
The severity of the disease is correlated 
with the length of the CGG tract. Affected 
males and females exhibit a massive ex-
pansion resulting in greater than 200 
copies or may increase, up to 1000 
repeats. Such expansions are called ‘full 
mutations’.  Nonpenetrant male and female 
carriers exhibit premutation alleles between 
60 and 200 copies (Sarah et al. 2003). 
Male carriers transmit only unstable 
premutations while female premutation 
carriers can have carrier offsprings with 
premutation or affected children with full 
mutations. The phenotypic manifestations 
of fragile X syndrome are not specific. 
These may include variable degrees of 
mental retardation, prominence of the jaw 
and forehead, dysmorphic ears, high-
arched palate, macrocephaly, macro-
orchidism and hyperactivity. Males with 
fragile X syndrome usually have mental 
retardation and often exhibit characteristic 
physical features and behavior. Affected 
females exhibit a similar but usually less 
severe phenotype, likely the result of ran-
dom X-inactivation patterns (Warren and 
Nelson 1994).   
The usual diagnostic analysis for fragile 
X syndrome is based on the detection of a 
fragile site by cytogenetic analysis, fol-
lowing specific cell culture conditions that 
modulate deoxynucleotide triphosphate 
levels. This however, has been difficult and 
sometimes inadequate for diagnosis 
(Rousseau et al. 1991), because other 
fragile sites such as FRAXE also exhibit 
the fragile site characteristics as FRAXA 
mutation (Warren and Nelson 1994). 
Molecular diagnosis of the CGG expansion 
mutation has been developed using 
Southern hybridization methods. However, 
the Southern hybridization tool is relatively 
expensive, time-consuming, laborious and 
requires large quantities of genomic DNA 
(Soon et al. 2001). Methods using PCR 
technique appears to be rapid and efficient 
for screening (Brown et al. 1993). It utilizes 
flanking of specific primers to amplify a 
fragment of DNA spanning the repeat 
region. In this study, the PCR analysis was 
verified using DNA obtained from a fragile 
X family, two cases with unrelated mental 
retardation, and a normal control. Thus, the 
aim of this study is to establish a rapid and 
simple PCR method as a screening tool for 
fragile X syndrome. 
 
MATERIALS AND METHODS 
 
Samples 
 
A total of six samples were analysed. One 
of the samples was taken from a known 
fragile X positive male patient (T1), who 
was referred to the Haematology Unit. In 
1998. Blood samples were also collected 
from his mother (T2) and father (T3) for 
cytogenetic analysis. The other two 
samples (T4 and T5) were randomly 
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selected, that is from two patients 
presenting with dysmorphic features and 
delay in development. The control (TC) 
sample was taken from a normal healthy 
female, who was cyto-genetically negative 
for the FRAXA gene at the fragile site. A 
detailed family history was obtained from 
all these cases. 
 
Cytogenetic Analysis 
 
Peripheral blood lymphocytes were cul-
tured according to standard laboratory pro-
tocol for fragile X analysis. A combination 
of the two-culture system was used. These 
included lymphocyte culture (Fragile X cul-
ture) under folic acid and thymidine defi-
cient condition (media 199 with 5% bovine 
serum, antibiotics penicillin and strepto-
mycin, and PHA) and the other was a syn-
chronised lymphocyte culture (1640 media 
with 5% fetal bovine serum, antibiotics 
penicillin and streptomycin, PHA and thy-
midine 0.1 M final concentration). All cul-
tures were incubated at 37 °C for 72 hours. 
The culture was harvested after adding 0.1 
ml colcemid (10µg/ml) for 7 minutes for the 
fragile X culture. 0.2ml (20µg/ml) of col-
cemid was added 1 hour before harvesting 
time for the synchronised culture. The cul-
tures were treated with 0.075M potassium 
chloride (hypotonic solution) and fixed in 
3:1 methanol acetic acid mixtures. Slides 
were aged and Leishman banding was 
carried out. At least 50 to 100 well spread, 
stained metaphases were scored to deter-
mine the presence of the fragile site on the 
X chromosome. Fragile sites appear as 
non-stainning regions, chromatid gaps, or 
less frequently, as breaks near the terminal 
end of the long arm of the X chromosome. 
Banded metaphases from the synchro-
nised culture were also analysed to 
exclude the presence of chromosomal 
aberrations. Karyotyping was carried out 
using an image analyser (CytoVision, 
Applied Imaging). 
 
 
 
DNA Extraction 
 
DNA extraction was performed at the time 
of diagnosis. Samples were collected in 
ethylenediamine-tetraacetic acid (EDTA) 
tube and DNA was extracted from whole 
blood using the standard protocol of lysis; 
proteinase K digestion, followed by ex-
traction with a combination of phenol and 
chloroform and precipitation with cold 
ethanol.  The extracted DNA is aliquot and 
stored at -20°C. 
 
PCR Amplification and Analysis 
 
The archived DNA samples were subjected 
to a touch-down PCR analysis based on a 
slight modification of a previously des-
cribed method (Tan et al. 2000). In this 
modified method, the enzyme AmpliTaq 
polymerase was replaced with the enzyme 
AmpliTaq (gold) polymerase. Amplification 
was carried out in a thermocycler in 30 µl 
reactions containing approximately 300ng 
of DNA template, PCR buffer, 10 pmol 
each of primers g (forward primer) and f 
(reverse primer),  1.5 U of AmpliTaq (gold) 
polymerase (Perkin Elmer), 10% dimethyl 
sulphoxide (DMSO) and 200µM each 
dNTP. dGTP was substituted with 7-deaza-
2’ dGTP in a ratio of dGTP (1.2) : 7-deaza-
dGTP (1.0) to amplify the mutated alleles.  
For the negative control, DNA template 
was replaced by RNase free water.  
The reaction mixture went through a 
‘touch-down procedure’;  denaturation at 
95°C for 8 minutes, followed initially by 5 
cycles of denaturation at 95°C for 90 
seconds, annealing at 70°C to 66°C 
(decreasing by 1°C per cycle) for 60 
seconds and elongation at 72°C for 120 
seconds. The reaction mixture was then 
subjected to 35 cycles of amplification at 
95°C for 90 seconds, 65°C for 60 seconds, 
72°C for 120 seconds, and a final exten-
sion of 10 minutes at 72°C. The PCR 
products were analysed on 1.0% agarose 
gel containing ethidium bromide using the 
gel documentation system. The amplicon 
sizes were determined by using a 100bp 
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standard DNA ladder. The presence of a 
band of the correct size approximately 
522bp for the normal alleles excludes the 
presence of an expansion mutation at the 
FRAXA locus. An increased number of 
CGG repeats revealed no detectable band 
on the gel, indicating full mutation of the 
FRAXA gene in an affected individual. 
PCR analysis was carried out on all 
genomic DNA samples. The migrations of 
PCR products were analysed. As 
presented in figure 2.0, the presence of a 
522bp band (for the normal allele) was 
observed in lanes 1, 3, 4, 5 and 6, thus 
excluding the presence of an expansion 
mutation at the FRAXA locus. The sample 
(T1) from the known case of fragile X 
syndrome (lane 2) showed absence of this 
PCR product, (figure 2.0) indicating that he 
may have the full mutation.  
 
RESULTS 
 
Results of the cytogenetic analysis showed 
no chromosomal aberrations in five (T2, 
T3, T4, T5, TC) out of six samples  studied 
(Table 1.0). One sample (T1) demon-
strated presence of a fragile-site. The fra-
gile site appears as a gap or break on the 
long arm of the X chromosome (Figure 
1.0). All of the samples however, showed 
cytogenetically normal karyotypes using 
banded metaphases. 
The family history of the known fragile-X 
positive patient (T1) revealed that both of 
his male siblings have characteristics of 
mental retardation and facial dysmorphic 
features of fragile X syndrome. The family 
of the other five cases showed no history of 
mental retardation among their siblings and 
parents. 
 
 DISCUSSION 
Table 1:  Summary of results of cytogenetic analysis, 
fragile site detection and PCR analysis of 
the FRAXA locus 
 
 
Results 
Cytogenetic Analysis PCR Analysis     Sample Sex 
Karyotype 
Presence 
of Fragile 
site 
Presence 
of 522bp 
product 
T1 Male 46,XY     
Normal male 
karyotype 
Yes Absence 
T2 Female 46,XX     
Normal 
female 
karyotype 
No Present 
T3 Male 46,XY      
Normal male 
karyotype 
No Present 
T4 Male 46,XY     
Normal male 
karyotype 
No Present 
T5 Male 46,XY     
Normal male 
karyotype 
No Present 
C Female 46,XX     
Normal 
female 
karyotype 
No Present 
Over the past few years, the diagnosis of 
fragile X syndrome was based on the 
presence of a folate-sensitive fragile site at 
Xq27.3 (FRAXA) induced in cell cultures 
under conditions of folate deprivation. In 
this study, cytogenetic analysis of the 
affected individual (T1) showed fragile sites 
at the distal end of the long arm of 
chromosome X (figure 1.0) when cultured 
under folate deficient conditions. However, 
cytogenetic analysis was unable to 
determine whether the breakage or gap 
resulted from expansion of the FRAXA 
gene or from other fragile sites genes. For 
instance, other fragile sites such as FRAXE 
(Xq28), that is located approximately 600 
kilobases distal to FRAX, also exhibit 
fragile sites under folate deficient culture 
(Knight et al. 1993). This has led to 
difficulty in the interpretation of fragile sites 
using the conventional cytogenetic method. 
Cytogenetic analysis is less sensitive for 
detecting affected individuals. It also 
results in a high degree of variability 
between individuals and laboratories. 
Our PCR analysis utilises flanking 
specific primers to amplify fragments of  
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Figure 1: Partial karyotype of G-banded (left) and stained (right) fragile X chromosome 
(arrow indicating the fragile sites) 
 
 
 
 
 
                                                                                                                                                 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2: Gel electrophoresis showing Polymerase chain reaction (PCR) product of 
FRAXA locus. Lane 1 (light band) is normal female control (TC), lanes 2 to 6 are 
patients’ samples (T1, T2, T3, T4, and T5 respectively). Lane 7 is a negative 
control (NC).M is the100bp DNA ladder 
 
 
 
                        
 Lanes:         1      2      3    4     5     6     7
                           M   TC    T1    T2   T3  T4    T5    NC
 
 
 
 
 
 
 
 
 
DNA spanning the repeat region. It 
amplifies the normal repeat size or those 
that are within the normal range, thus 
produces products of the expected size 
(figure 2.0).  As expected, in the affected 
patient (T1), there is absence of the band, 
indicating full mutation of the FRAXA 
alleles, because the repeats are too large 
to be amplified (Soon et al. 2001; Wang et 
al. 1993). However, expansion involving 
other fragile site genes which demon-
strated breakage under folate deficient 
conditions, will be amplified, and detectable 
bands will be observed on the electro-
phoresis gel. Thus, the PCR analysis is 
specific for detection of the FRAXA full 
mutation. It is also able to differentiate it 
from expansion due to other fragile site 
genes. 
The modified PCR analysis as outlined 
500bp 
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in this study is more sensitive and 
informative as a screening tool for 
detecting full mutation, compared to 
cytogenetic analysis. The method has its 
limitations in that it is unable to give an 
accurate size determination of full muta-
tions and also to distinguish between nor-
mal and fragile X premutation carrier indivi-
duals. Affected patients showing absence 
of the expected band and females who 
show normal CGG allele should therefore 
be investigated further using Southern 
blotting. Although the Southern blot is the 
key diagnostic tool to detect the mutations 
of the fragile X syndrome, it is relatively 
laborious, time consuming, needs large 
quantities of DNA material, and is expen-
sive. It is therefore not a suitable method 
for routine screening of fragile X syndrome. 
Studies of family pedigrees are im-
portant because they help in excluding 
male transmission of fragile X and also to 
determine the carrier status. For instance, 
the family history of the affected male 
revealed that both of his male siblings also 
showed characteristics of fragile X syn-
drome, namely mental retardation and 
facial dysmorphic features. However, cyto-
genetic and PCR analyses were not carried 
out on the male siblings because they were 
residing abroad at the time of diagnosis. 
The paternal family history was not signifi-
cant and revealed high intellectual capa-
cities in all generations. The mother of the 
affected male was suspected to be an obli-
gate fragile X carrier. Studies have shown 
that women who are pre-mutation carriers 
can have carrier offsprings with pre-muta-
tions or affected children with full mutations 
(Warren and Nelson 1994; Soon et al. 
2001; Pieretti et al. 1991). The chance that 
the allele will increase to full mutation 
depends on its size in the mother. All 
affected males and the majority of affected 
females inherit the mutation from their 
mother. The other two patients showed no 
family history of mental retardation.  
PCR amplification of CGG repeats in 
the FRAXA fragment is difficult, and special 
conditions are required. The incorporation 
of 7-deaza-2’ dGTP to stabilise secondary 
DNA structures allows successful ampli-
fication of the CG-rich region (Tan et al. 
2000; Latimer and Lee 1991). However, 
PCR products with a high content of 7-
deaza-2’ dGTP, do not stain efficiently with 
ethidium bromide (Innis 1990; Latimer and 
Lee 1991).  Presumably, the presence of 7-
deaza-2’ dGTP alters the electronic struc-
ture of bound ethidium so that it can no 
longer fluoresce (Latimer and Lee 1991).  
 To investigate whether these changes 
may be an appropriate alternative to the 
described procedure, we have used the 
ratio 1.0: 1.2 respectively of 7-deaza-2’ 
dGTP to dGTP instead of 1: 1 ratio as 
previously described (Tan et al. 2000). We 
found that by changing the ratio of 7-
deaza-2’ dGTP to dGTP , our PCR reaction 
was able to successfully amplify the 
FRAXA allele within the normal range. 
Together with efficient staining by ethidium 
bromide direct visualization of the PCR 
product under ultraviolet light was 
obtained. Omitting 7-deaza-2’ dGTP or 
lowering the ratio of 1.0 : 1.2 of 7-deaza-2’ 
dGTP to dGTP is not recommended be-
cause it will increase secondary DNA 
structures in the PCR reaction. This may 
result in non-specific bands appearing 
during electrophoresis. The minor changes 
of using AmpliTaq Gold®DNA polymerase 
rather than AmpliTaq polymerase as a 
chemical hot start enzyme has resulted in 
the increased specificity and product yield 
without biological contamination of the 
PCR reaction. This modification has led to 
increased sensitivity of the reaction, dimi-
nishing the formation of non-specific pro-
duct while allowing detection of low target 
copy number of the PCR product.   
 Interpretation of fragile X also poses 
some problems. The usual precautions for 
the prevention of contamination of the PCR 
product must be observed. Shadow or 
heteroduplex bands must be distinguished 
between true abnormal alleles when non-
denaturing electrophoresis is used. Lane 
background and faint bands are other 
problems faced and these should be inter-
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preted with caution as smears of expanded 
fragments can be very faint. 
The PCR analysis carried out in this 
study is a basic and simple technique that 
is completely independent of methylation 
and is specific for the FRAXA locus. Our 
study indicated that PCR analysis using 
specific primers was more sensitive than 
cytogenetic analysis to screen for full muta-
tion of the fragile site. Southern blot ana-
lysis should still be used for confirmation of 
the presence of an expanded allele. Typi-
cally, molecular diagnostic services should 
include a combination of both Southern 
blot-based and PCR-based analysis to 
cover instances in which one or both types 
of tests are needed. G-banded karyotyping 
should be routinely performed as constitu-
tional chromosome abnormalities have 
been identified as frequently as FMR-1 
mutations in mentally retarded individuals 
referred for fragile X testing. Laboratories 
often need to use more than one method 
because no single method can detect all 
types of mutations equally well or with 
equal weakness (Maddalena et al. 2000).  
 
CONCLUSION 
 
In conclusion, we have established a 
simple PCR analysis for screening fragile X 
syndrome. The PCR is an alternative 
method with advantages for mutational 
analysis. It is rapid, sensitive and uses 
minimal DNA. We recommend that labo-
ratories use PCR as a screening tool for 
fragile X syndrome. Family history should 
also be evaluated to assist in the diag-
nostic screening and to determine the risk 
of having affected children. Southern blot 
should also be carried out to detect repeat 
trinucleotide and methylation status for 
samples that have failed to amplify (male) 
or show a normal allele (females). In spite 
of the advances in molecular testing, rou-
tine G-banded cytogenetic analysis should 
still be performed particularly for cases of 
unexplained learning difficulties and deve-
lopmental delay to exclude other chromo-
somal abnormalities.  
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